Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab

被引:25
|
作者
Chou, Shaun [1 ]
Hwang, Shelley Ji Eun [2 ,3 ]
Carlos, Giuliana [2 ,3 ]
Wakade, Deepal [2 ,3 ]
Fernandez-Penas, Pablo [2 ,3 ]
机构
[1] Westmead Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia
[2] Westmead Hosp, Dept Dermatol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
关键词
PD-1; nivolumab; pembrolizumab; CTLA-4; ipilimumab; immunotherapy; lichenoid inflammation; lichen planus; adverse drug reaction; ADVANCED MELANOMA; METASTATIC MELANOMA; UNTREATED MELANOMA; PEMBROLIZUMAB; NIVOLUMAB; PATHWAY; COHORT; CANCER; SAFETY;
D O I
10.1097/DAD.0000000000000587
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Lichenoid drug reaction is a common adverse reaction in patients taking immune-modulatory agents such as antiprogramed cell death (PD-1) and cytotoxic T lymphocyte antigen-4 agents. The authors describe the clinical and histologic features of lichenoid drug reaction in 20 biopsies from 15 patients on anti-PD-1 agents and 9 biopsies from 7 patients on anti-PD-1 plus ipilimumab therapy. Clinically, all except 2 patients presented with discrete, violaceous exanthematous papules to plaques. The lichenoid inflammation in the majority (18 of 29 biopsies) was florid although histology was quite heterogeneous. Nevertheless, there was frequent involvement of the superficial follicular epithelium and acrosyringium, and also a propensity to blister that occurred in approximately 20% of the biopsies. Occasional patients had disease closely resembling lichen planus, although all of these biopsies had some atypical features for lichen planus such as parakeratosis. Dermal eosinophils were common particularly in those with mild inflammation. The lichenoid reaction was responsive to topical steroid or oral systemic treatment in general, and the anti-PD-1 agent had to be ceased in only one patient.
引用
收藏
页码:23 / 27
页数:5
相关论文
共 50 条
  • [41] Cutaneous toxicities of anti-programmed death (anti-PD-1) antibodies in patients with advanced solid organ tumours
    Hwang, S. J. E.
    Wakade, D.
    Byth, K.
    Chou, S.
    Hui, R.
    Gurney, H.
    Fernandez-Penas, P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 61 - 61
  • [42] Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
    Tartarone, Alfredo
    Roviello, Giandomenico
    Lerose, Rosa
    Roudi, Raheleh
    Aieta, Michele
    Zoppoli, Pietro
    FUTURE ONCOLOGY, 2019, 15 (20) : 2423 - 2433
  • [43] Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis
    Yang, Yuanquan
    Mori, Sherry, V
    Li, Mingjia
    Hinkley, Megan
    Parikh, Anish B.
    Collier, Katharine A.
    Miah, Abdul
    Yin, Ming
    CANCER MEDICINE, 2022, 11 (07): : 1669 - 1677
  • [44] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
    Hamid, Omid
    Chow, Laura Quan Man
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies
    Song, Xuyang
    Khan, Anis A.
    Zhou, Diansong
    Elgeioushi, Nairouz
    Walcott, Farzana
    Ren, Song
    Gibbs, Megan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 373 - 382
  • [46] Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
    Que, Yi
    Wang, Juan
    Sun, Feifei
    Wang, Shan
    Zhu, Jia
    Huang, Junting
    Zhao, Zhenzhen
    Zhang, Li
    Liu, Juan
    Xu, Jiaqian
    Zhen, Zijun
    Sun, Xiaofei
    Lu, Suying
    Zhang, Yizhuo
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [47] Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
    Yi Que
    Juan Wang
    Feifei Sun
    Shan Wang
    Jia Zhu
    Junting Huang
    Zhenzhen Zhao
    Li Zhang
    Juan Liu
    Jiaqian Xu
    Zijun Zhen
    Xiaofei Sun
    Suying Lu
    Yizhuo Zhang
    Signal Transduction and Targeted Therapy, 8
  • [48] Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
    Naing, Aung
    Infante, Jeffrey
    Goel, Sanjay
    Burris, Howard
    Black, Chelsea
    Marshall, Shannon
    Achour, Ikbel
    Barbee, Susannah
    May, Rena
    Morehouse, Chris
    Pollizzi, Kristen
    Song, Xuyang
    Steele, Keith
    Elgeioushi, Nairouz
    Walcott, Farzana
    Karakunnel, Joyson
    LoRusso, Patricia
    Weise, Amy
    Eder, Joseph
    Curti, Brendan
    Oberst, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [49] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies
    Xuyang Song
    Anis A. Khan
    Diansong Zhou
    Nairouz Elgeioushi
    Farzana Walcott
    Song Ren
    Megan Gibbs
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 373 - 382
  • [50] Extended duration of anti-PD-1 therapy, using reduced frequency dosing, in patients with advanced melanoma and Merkel cell carcinoma
    Tachiki, Lisa May Ling
    Silva, Karly Williams
    Hippe, Daniel S.
    Fritzsche, Dane
    Raczka, Aleksandra
    Perdue, Andrea
    Majovski, Julia
    Spallone, Alexandra
    Goldstein, Daniel A.
    Nghiem, Paul
    Thompson, John A.
    Hall, Evan Thomas
    Bhatia, Shailender
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)